The latest version of the National Comprehensive Cancer Network guidelines in 2023 recommends osimertinib as the first choice for systemic treatment in patients with non–small cell lung cancer (NSCLC) harboring an EGFR L858R mutation. Here, EGFR is linked to non-small cell lung carcinoma.